Life Sciences Licensing & Collaborations

We are consistently recognized among the top practitioners in intellectual property, licensing, and life sciences transactions, with honors reflecting our impact on high-value collaborations and royalty monetization.

• Chambers USA – “Healthcare & Life Sciences Law Firm of the Year” (2026)
• Chambers USA – Intellectual Property
• The Legal 500 US – Intellectual Property
• Managing IP Americas Awards – IP Transactions Firm of the Year (2023, 2025)
  • Sarepta Therapeutics and Arrowhead Pharmaceuticals $11.35 billion collaboration agreement
  • Novo Nordisk and Valo Health $2.7B collaboration agreement
  • Eli Lilly and TrexBio $1.1B collaboration agreement
• LMG Life Sciences – Licensing & Collaboration Firm of the Year (2018, 2020–2021, 2023–2024)
• Law360 – Life Sciences Practice Group of the Year (2006-2026)
• Best Lawyers in America – Biotechnology & Life Sciences (2022–2025)
• Massachusetts Lawyers Weekly – Go-To Lawyers, Healthcare & Life Sciences (2024)

Our team has guided pharmaceutical, biotechnology, and medical device companies through complex licensing transactions and strategic collaborations that advance product development pipelines and expand market access.

• Adaptimmune:
  • in its $3+ billion strategic collaboration with Genentech to research, develop and commercialize cancer-target allogeneic T-cell therapies, under which the companies will combine their technologies and expertise to research and develop “off-the-shelf” cell therapies for up to five cancer targets and develop a novel allogeneic personalized cell therapy platform.
  • in a co-development and co-commercialization agreement with Astellas Pharma worth up to $897.5 million to identify and develop new stem-cell derived allogeneic T-cell therapies to cancer patients.
• Asimov on licensing and IP counseling for synthetic biology and computer-aided therapeutic design platforms.
• Bain Capital in a license and collaboration agreement between One Bio and Jiangsu Hengrui Pharmaceutical Co. Ltd. worth $1.05 billion to develop, produce and commercialize an asthma and chronic sinusitis-targeting drug, SHR-1905 worldwide, excluding the greater China territory.
• Eli Lilly and Company (Lilly) in a strategic collaboration with Repertoire Immune Medicines to develop tolerizing T cell therapies for multiple autoimmune diseases in a deal worth up to $1.9 billion.
• Everest Medicines in an exclusive licensing and collaboration agreement for the development and commercialization of Brunton’s tyrosine kinase (BTK) inhibitor, called civorebrutinib, an oral therapy designed to treat rare immune-mediated kidney diseases in a deal worth up to $1.14 billion
• Singapore-based biotechnology company Gero PTE. LTD. in a joint research and license agreement up to $1 billion with Tokyo-based Chugai Pharmaceutical Co, Ltd., a member of Roche Group, to develop novel antibody therapies for age-related diseases.
• Ginkgo Bioworks in a five-year AI and cloud computing partnership with Google Cloud supporting AI tools for biology and biosecurity applications.
• Gilgamesh Pharmaceuticals:
  • in a collaboration and option-to-license agreement with AbbVie, valued up to over $2 billion, to develop next-generation therapies for psychiatric disorders.
  • in an agreement to sell its lead investigational candidate, bretisilocin, to AbbVie for up to $1.2 billion, inclusive of an upfront payment and development milestones. Bretisilocin is a potential best-in-class psychedelic compound for the treatment of patients with moderate to severe major depressive disorder.
• Genesis Molecular AI, a Stanford University spin-out company with a focus on artificial intelligence:
  • in a multi-target collaboration with Genentech, a member of the Roche Group.
  • in a five-target collaboration with Eli Lilly and Company, with payments to Genesis up to $670 million.
• iTeos Therapeutics, a Belgian biopharmaceutical company, in a $2 billion collaboration with global health care leader GSK to co-develop and co-commercialize an anti-TIGIT monoclonal antibody as a potential treatment for cancer patients.
• Iterative Health in AI and machine learning-based strategic partnerships for computational gastroenterology and precision medicine applications.
• Lepu Biopharma in a $1.6 billion exclusive license agreement with ArriVent BioPharma for novel antibody-drug conjugate (ADC) MRG007, in development for gastrointestinal cancers.
• Madrigal Pharmaceuticals:
  • in an exclusive global license agreement with Suzhou Ribo Life Sciences Co. and its subsidiary Ribocure Pharmaceuticals AB worth up to $4.4 billion.
  • in an exclusive global license agreement worth up to $2 billion with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist.
  • in an exclusive global license agreement with Arrowhead Pharmaceuticals for up to $1 billion for a clinical stage small-interfering RNA candidate, ARO-PNPLA3.
• MOMA Therapeutics in a strategic collaboration and licensing agreement with Roche in a transaction worth over $2 billion that will provide Roche with access to MOMA’s KnowledgeBase platform for the identification of a certain number of novel drug targets involved in promoting cancer cell growth and survival.
• Monte Rosa Therapeutics:
  • in a collaboration agreement with Novartis to develop novel molecular glue degrader-based medicines for immune diseases in a deal worth up to $5.7 billion.
  • in a global exclusive licensing agreement with Novartis to develop and commercialize a molecular glue degrader (MGD) drug for immune-related diseases worth up to $2.25 billion.
• Neomorph in a research collaboration with Biogen with a total consideration of up to $1.45 billion, to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases.
• Nona Biosciences:
  • in a license agreement with AstraZeneca, valued at up to $604 million, for preclinical monoclonal antibodies that will be used to develop targeted oncology therapies using Nona’s antibody discovery platform.
  • in an exclusive license agreement with Pfizer (Seagen), valued at up to $1.58 billion, for the rights to Nona’s mesothelin-targeted antibody-drug candidate HBM9033.
• Novo Nordisk:
  • in expanding its collaboration with Valo Health in a deal worth up to $4.6 billion to discover and develop new treatments using artificial intelligence and real-world patient data to develop up to 20 treatments for obesity, type 2 diabetes and cardiovascular disease.
  • in a partnership agreement with Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated diseases in oral formulations for up to $2.1 billion.
  • in an asset purchase and license agreement with Omeros Corporation for Omeros’ drug candidate zaltenibart, a potential best-in-class treatment for rare blood and kidney disorders, in a deal worth up to $2.1 billion.
• Numerion Labs, an artificial intelligence-based drug discovery company in a strategic five-target research collaboration with Sanofi, with potential payments totaling $1.2 billion.
• Pfizer:
  • its global licensing and collaboration agreement with China-based Innovent Biologics for the research and development of 12 innovative cancer medicines worth up to $10.5 billion. 
  • its $1.24 billion ex-U.S. strategic collaboration agreement with Biohaven to commercialize rimegepant.
  • in a research collaboration and subsequent $74 million acquisition of ResApp Health, a mobile AI platform for respiratory disease detection.
• Recursion Pharmaceuticals in its collaboration with Enamine to generate AI-enabled molecular screening libraries using machine learning-based protein-ligand prediction tools.
• Sanofi:
  • in a strategic collaboration with Dren Bio to develop a next-generation B-cell depleting therapy for autoimmune diseases in a deal worth up to $1.7 billion.
  • in negotiating a $1+ billion strategic collaboration with BioMap under which the parties would leverage BioMap’s AI engine and Sanofi’s deep biologics development experience to create advanced AI models and protein large language models for Sanofi to use to advance its novel biologic drug discovery and development pipeline.
  • in an exclusive worldwide collaboration with Skyhawk Therapeutics for up to more than $2 billion to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology disease targets with limited or no therapeutic options.
• Shape Therapeutics in a strategic collaboration with Roche worth up to $3 billion to use Shape’s RNA-editing platform and adeno-associated virus (AAV) technology to identify and develop treatments for Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.
• SK Biopharmaceuticals in a research and development collaboration with Insilico Medicine to discover AI-enabled drug candidates in neuroimmune disorders of the central nervous system in a deal worth up to $2.5 billion.
• Vir Biotechnology:
  • in its global collaboration with Astellas Pharma to develop and commercialize VIR-5500, an investigational dual-masked T-cell engager for advanced prostate cancer, with upfront and near-term payments of $335 million, a U.S. profit share, and potential milestones and royalties totaling up to $1.7 billion
  • in an exclusive worldwide license agreement with Sanofi for three clinical stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases.
• Xilio Therapeutics in a strategic collaboration and option agreement with AbbVie to discover and develop tumor-activated immunotherapies, including masked T cell engagers, in a deal worth up to $2.1 billion.
• A biopharmaceutical company in an AI-enabled research collaboration worth up to $5.3 billion with a China-based pharmaceutical group to advance the discovery and development of novel oral drug candidates across multiple disease indications.
• A leading global pharmaceutical company in a collaboration and license agreement with a Belgium research university to develop potential treatments for respiratory syncytial virus (RSV) infection.
• A leading global biopharmaceutical company in a $2 billion license and collaboration agreement with a Danish biotechnology company for access to proprietary antibody conjugation technology platforms to develop antibody-drug conjugates (ADCs).
• A leading global biopharmaceutical company in a strategic partnership for up to $1.7 billion with Denmark-based pharmaceutical company to advance development and commercialization of programs to treat patients with multiple chronic inflammatory diseases including atopic dermatitis, asthma and chronic obstructive pulmonary disease (COPD), among others.
• A leading global biopharmaceutical company in a $1.25 billion license and collaboration agreement with a Korean biotechnology company for access to proprietary antibody conjugation technology platforms to develop antibody-drug conjugates (ADCs) directed against up to five targets.
• Several biopharmaceutical companies on the use of AI for drug development, including assistance with contract negotiation, vendor qualification best practices, and the creation of internal AI governance policies, all within the complex regulatory landscape of FDA requirements.